Peptide ReadinessJoin the beta
Back to database

FDA 2026 COMPOUNDING REVIEW

Epitalon

A longevity market peptide anchored to a formal FDA bulk substance review without becoming an FDA approved treatment.

Record version 1.0Last verified 5 September 2026Evidence grade CRegulatory surveillance cohort
FDA STATUS

Not FDA approved; advisory review is not drug approval

MHRA / UK LICENCE

No UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access

PRIVATE LAWFUL USE CONTEXT

Research market presence is not licensed clinical use

EVIDENCE MATURITY

Limited modern human evidence relative to longevity claims

DEVELOPMENT PHASE

Regulatory surveillance cohort

MARKET EXPOSURE

High longevity market

PROFESSIONAL RELEVANCE

Use as a flagship example of why regulatory event tracking needs precise language and evidence grading.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

Production baseline verification recorded.

FDA PCAC reviewed a 503A bulk substance nomination in July 2026

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.